{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-23-000060","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.506890+00:00","generated_at":"2026-06-10T07:37:55.578575+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elicio reports ELI-002 Phase 1 data: median RFS not reached vs 3.9 months, HR=0.14","bullets":["Median RFS not reached for high T cell responders vs 3.9 months for low (HR=0.14; p=0.013).","86% reduction in risk of progression or death in patients with large T cell responses.","Tumor biomarker reduction/clearance -86.9% vs -1.0% in above vs below median T cell responders (p<0.0017).","Plan to initiate randomized Phase 2 study of ELI-002 7P in adjuvant PDAC patients early 2024.","No ≥Grade 3 treatment-related AEs; safety profile supports further development."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-23-000060","json":"https://secwatch.observer/filing/0001601485-23-000060.json","markdown":"https://secwatch.observer/filing/0001601485-23-000060.md","text":"https://secwatch.observer/filing/0001601485-23-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000060/0001601485-23-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000060/angn-20230927.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:37:55.578575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}